Skip to content

More evidence that earlier treatment provides greatest benefit for children with HIV

Looking forward to 2004: microbicide and ARV prevention prospects

Looking forward to 2004: HIV vaccine prospects

Looking forward to 2004: treatment for hepatitis C

Ritonavir price increase: what are the consequences in 2004?

US doctors plan cross the board Abbott product boycott after 400% ritonavir price hike

More bad news on tenofovir/abacavir/3TC

Better clinical outcomes if HAART started before CD4 cell count falls below 200

Landmark study shows why AZT/3TC/efavirenz now preferred as first-line HIV treatment